Related Experiment Video
Updated: Jun 16, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
CDBN-YGXZ shows highly antibacterial activity against Clostridioides difficile as a potential candidate drug
Xiaoxia Zhang1, Min Quan1, Xin Lu1
1Centre of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.
Abstract:
CDBN-YGXZ shows a low minimal inhibitory concentration range from 0.015 to 0.125 mg/L against clinical Clostridioides difficile strains with diverse genotypes, hardly induces bacterial resistance, and intensively inhibits 86.2 % of C. difficile adhesion to intestinal epithelial cells Caco-2. CDBN-YGXZ shows highly antibacterial activity and is potentially a candidate as a therapeutic drug.
More Related Videos
12:58A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Antibiotic Selection
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...